ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Withdrawn before enrolling · Phase 1
Conditions studied: Acute Myeloid Leukemia
In brief
This is a single-center open-label phase I clinical trial of delivering haploidentical natural killer (NK) cells matured ex vivo with ALT-801 followed by intravenous infusions of ALT-801 in patients with relapsed/refractory Acute Myeloid Leukemia (AML). The study will be conducted at M.D. Anderson Cancer Center (MDACC) and MDACC Children's Cancer Hospital in Houston, Texas.
Key facts
- Study ID
- NCT01478074
- Run by
- Altor BioScience
- People needed
- 0
- Starts
- 2011-11-01
- Expected to finish
- 2013-11-01
- Last updated by the study team
- 2014-01-03
Who can join
Age: 2 and older, up to 59. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.